136 related articles for article (PubMed ID: 27118336)
1. Functional and mechanistic analysis of telomerase: An antitumor drug target.
Chen Y; Zhang Y
Pharmacol Ther; 2016 Jul; 163():24-47. PubMed ID: 27118336
[TBL] [Abstract][Full Text] [Related]
2. Telomerase Inhibitors from Natural Products and Their Anticancer Potential.
Ganesan K; Xu B
Int J Mol Sci; 2017 Dec; 19(1):. PubMed ID: 29267203
[TBL] [Abstract][Full Text] [Related]
3. [Telomere and telomerase as targets for anti-cancer drugs].
Ide T
Nihon Rinsho; 2004 Jul; 62(7):1271-6. PubMed ID: 15283143
[TBL] [Abstract][Full Text] [Related]
4. Telomere maintenance as a target for drug discovery.
Sekaran V; Soares J; Jarstfer MB
J Med Chem; 2014 Feb; 57(3):521-38. PubMed ID: 24053596
[TBL] [Abstract][Full Text] [Related]
5. Targeting human telomerase in cancer therapy.
Huard S; Autexier C
Curr Med Chem Anticancer Agents; 2002 Sep; 2(5):577-87. PubMed ID: 12678725
[TBL] [Abstract][Full Text] [Related]
6. Bortezomib-mediated down-regulation of telomerase and disruption of telomere homeostasis contributes to apoptosis of malignant cells.
Ci X; Li B; Ma X; Kong F; Zheng C; Björkholm M; Jia J; Xu D
Oncotarget; 2015 Nov; 6(35):38079-92. PubMed ID: 26472030
[TBL] [Abstract][Full Text] [Related]
7. Targeting telomeres and telomerase.
De Cian A; Lacroix L; Douarre C; Temime-Smaali N; Trentesaux C; Riou JF; Mergny JL
Biochimie; 2008 Jan; 90(1):131-55. PubMed ID: 17822826
[TBL] [Abstract][Full Text] [Related]
8. Roles of telomeres and telomerase in cancer, and advances in telomerase-targeted therapies.
Jafri MA; Ansari SA; Alqahtani MH; Shay JW
Genome Med; 2016 Jun; 8(1):69. PubMed ID: 27323951
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological intervention strategies for affecting telomerase activity: future prospects to treat cancer and degenerative disease.
Tárkányi I; Aradi J
Biochimie; 2008 Jan; 90(1):156-72. PubMed ID: 17945408
[TBL] [Abstract][Full Text] [Related]
10. Telomere maintenance mechanisms as a target for drug development.
Bearss DJ; Hurley LH; Von Hoff DD
Oncogene; 2000 Dec; 19(56):6632-41. PubMed ID: 11426649
[TBL] [Abstract][Full Text] [Related]
11. Telomere biology of pediatric cancer.
Tabori U; Dome JS
Cancer Invest; 2007; 25(3):197-208. PubMed ID: 17530490
[TBL] [Abstract][Full Text] [Related]
12. Telomere inhibition and telomere disruption as processes for drug targeting.
Rezler EM; Bearss DJ; Hurley LH
Annu Rev Pharmacol Toxicol; 2003; 43():359-79. PubMed ID: 12540745
[TBL] [Abstract][Full Text] [Related]
13. Telomeres and telomerase: understanding basic structure and potential new therapeutic strategies targeting it in the treatment of cancer.
Sekhri K
J Postgrad Med; 2014; 60(3):303-8. PubMed ID: 25121374
[TBL] [Abstract][Full Text] [Related]
14. Advances in the molecular design of potential anticancer agents via targeting of human telomeric DNA.
Maji B; Bhattacharya S
Chem Commun (Camb); 2014 Jun; 50(49):6422-38. PubMed ID: 24695755
[TBL] [Abstract][Full Text] [Related]
15. Correlation of chemosensitivity to anticancer drugs and telomere length, telomerase activity and telomerase RNA expression in human ovarian cancer cells.
Kiyozuka Y; Yamamoto D; Yang J; Uemura Y; Senzaki H; Adachi S; Tsubura A
Anticancer Res; 2000; 20(1A):203-12. PubMed ID: 10769656
[TBL] [Abstract][Full Text] [Related]
16. Anticancer therapy targeting telomeres and telomerase : current status.
Parkinson EK; Minty F
BioDrugs; 2007; 21(6):375-85. PubMed ID: 18020621
[TBL] [Abstract][Full Text] [Related]
17. Targeting the limitless replicative potential of cancer: the telomerase/telomere pathway.
Kelland L
Clin Cancer Res; 2007 Sep; 13(17):4960-3. PubMed ID: 17785545
[TBL] [Abstract][Full Text] [Related]
18. [Telomerase: an enzyme with multiple applications in cancer research].
Castillo Ureta H; Barrera Saldaña HA; Martínez Rodríguez HG
Rev Invest Clin; 2002; 54(4):342-8. PubMed ID: 12415959
[TBL] [Abstract][Full Text] [Related]
19. Acquired cellular resistance to flavopiridol in a human colon carcinoma cell line involves up-regulation of the telomerase catalytic subunit and telomere elongation. Sensitivity of resistant cells to combination treatment with a telomerase inhibitor.
Incles CM; Schultes CM; Kelland LR; Neidle S
Mol Pharmacol; 2003 Nov; 64(5):1101-8. PubMed ID: 14573759
[TBL] [Abstract][Full Text] [Related]
20. New prospects for targeting telomerase beyond the telomere.
Arndt GM; MacKenzie KL
Nat Rev Cancer; 2016 Aug; 16(8):508-24. PubMed ID: 27339602
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
